IL278471B2 - compounds containing bacterial strains - Google Patents

compounds containing bacterial strains

Info

Publication number
IL278471B2
IL278471B2 IL278471A IL27847120A IL278471B2 IL 278471 B2 IL278471 B2 IL 278471B2 IL 278471 A IL278471 A IL 278471A IL 27847120 A IL27847120 A IL 27847120A IL 278471 B2 IL278471 B2 IL 278471B2
Authority
IL
Israel
Prior art keywords
composition
bacterial strain
ncimb
therapy
seq
Prior art date
Application number
IL278471A
Other languages
English (en)
Hebrew (he)
Other versions
IL278471A (enExample
IL278471B1 (en
Original Assignee
4D Pharma Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810386.1A external-priority patent/GB201810386D0/en
Priority claimed from GBGB1813460.1A external-priority patent/GB201813460D0/en
Priority claimed from GBGB1817642.0A external-priority patent/GB201817642D0/en
Priority claimed from GBGB1820256.4A external-priority patent/GB201820256D0/en
Priority claimed from GBGB1820264.8A external-priority patent/GB201820264D0/en
Application filed by 4D Pharma Res Limited filed Critical 4D Pharma Res Limited
Publication of IL278471A publication Critical patent/IL278471A/en
Publication of IL278471B1 publication Critical patent/IL278471B1/en
Publication of IL278471B2 publication Critical patent/IL278471B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pediatric Medicine (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
IL278471A 2018-05-11 2020-11-03 compounds containing bacterial strains IL278471B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP18171893 2018-05-11
EP18178136 2018-06-15
GBGB1810386.1A GB201810386D0 (en) 2018-06-25 2018-06-25 Compositions comprising bacterial strains
GBGB1813460.1A GB201813460D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GBGB1817642.0A GB201817642D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GBGB1820256.4A GB201820256D0 (en) 2018-12-12 2018-12-12 Compositions comprising bacterial strains
GBGB1820264.8A GB201820264D0 (en) 2018-12-12 2018-12-12 Compositions comprising bacterial strains
PCT/EP2019/062238 WO2019215346A1 (en) 2018-05-11 2019-05-13 Compositions comprising bacterial strains

Publications (3)

Publication Number Publication Date
IL278471A IL278471A (enExample) 2020-12-31
IL278471B1 IL278471B1 (en) 2023-04-01
IL278471B2 true IL278471B2 (en) 2023-08-01

Family

ID=66597549

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278471A IL278471B2 (en) 2018-05-11 2020-11-03 compounds containing bacterial strains

Country Status (23)

Country Link
US (3) US11419902B2 (enExample)
EP (4) EP4056192A1 (enExample)
JP (3) JP7058449B2 (enExample)
KR (2) KR20210008391A (enExample)
CN (2) CN112512539A (enExample)
AU (3) AU2019267170A1 (enExample)
BR (1) BR112020022833A2 (enExample)
CA (2) CA3098971A1 (enExample)
CY (1) CY1125211T1 (enExample)
DK (1) DK3743086T3 (enExample)
ES (1) ES2916601T3 (enExample)
HR (1) HRP20220578T1 (enExample)
IL (1) IL278471B2 (enExample)
LT (1) LT3743086T (enExample)
MD (1) MD3743086T2 (enExample)
MX (1) MX2020012061A (enExample)
PL (1) PL3743086T3 (enExample)
RS (1) RS63273B1 (enExample)
SG (2) SG11202011028SA (enExample)
SI (1) SI3743086T1 (enExample)
SM (1) SMT202200217T1 (enExample)
TW (2) TW202014513A (enExample)
WO (2) WO2019215345A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009071A (es) 2017-01-31 2019-11-12 Univ Kansas State Celulas microbianas, metodos para producir las mismas, y usos de las mismas.
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
EP3697220A4 (en) 2017-10-20 2021-08-11 MS Biotech, Inc. PROCESS FOR PRODUCING SILAGED PLANT MATERIAL USING MEGASPHAERA ELSDENII
PL3743086T3 (pl) 2018-05-11 2022-06-20 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2022511975A (ja) * 2018-12-12 2022-02-01 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW202038979A (zh) * 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
CN112877275B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
CN112980878B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
EP4520816A1 (en) 2022-04-28 2025-03-12 Moon (Guangzhou) Biotech Co., Ltd. Pharmaceutical composition, megasphaera, and use thereof
EP4516892A1 (en) 2022-04-28 2025-03-05 Moon (Guangzhou) Biotech Co., Ltd. Pharmaceutical composition, megasphaera, and use thereof
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN117018036B (zh) * 2023-07-28 2025-09-05 深圳未知君生物科技有限公司 巨球形菌属细菌在制备治疗癌症的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5557520A (en) * 1978-10-26 1980-04-28 Nisshin Flour Milling Co Ltd Preparation of carcinostatic substance
EP1389464A4 (en) 2001-04-06 2005-06-22 Combi Co COMPOSITIONS WITH A BACTERIUM THAT MAY CONVERT MILKYLIC ACID TO BUTTERIC ACID, AND METHOD FOR THE PREVENTION / TREATMENT OF HYPERLACTACIDEMIA IN CARCINOMA IN DIGESTIVE TRAIN AND COLON USING THESE COMPOSITIONS
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015010096A1 (en) * 2013-07-18 2015-01-22 Baylor College Of Medicine Method of enhancing potency of immune cells
CN104415060A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
US10203329B2 (en) * 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9650654B2 (en) * 2014-06-25 2017-05-16 William Marsh Rice University Making C4+ products in bacteria
US10366793B2 (en) * 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
WO2016073381A1 (en) * 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10231941B2 (en) * 2015-01-23 2019-03-19 Temple University—Of The Commonwealth System of Higher Educaton Use of short chain fatty acids in cancer prevention
WO2016149449A1 (en) 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN108513545B (zh) * 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
PL3380108T3 (pl) * 2015-11-24 2023-03-27 Seres Therapeutics, Inc. Zaprojektowane kompozycje bakteryjne
WO2017122197A1 (en) * 2016-01-11 2017-07-20 3Plw Ltd. Lactic acid-utilizing bacteria genetically modified to secrete polysaccharide-degrading enzymes
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
WO2017172894A2 (en) * 2016-03-30 2017-10-05 The Trustees Of Columbia University In The City Of New York Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR102708641B1 (ko) * 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
WO2018094190A2 (en) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
US20190314427A1 (en) 2016-12-16 2019-10-17 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
CA3066189A1 (en) * 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000555T1 (it) * 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
PL3743086T3 (pl) * 2018-05-11 2022-06-20 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TW202038979A (zh) 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
JP2022511975A (ja) * 2018-12-12 2022-02-01 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物

Also Published As

Publication number Publication date
US11419902B2 (en) 2022-08-23
CA3098971A1 (en) 2019-11-14
US20230158083A1 (en) 2023-05-25
CA3099209A1 (en) 2019-11-14
AU2019267170A1 (en) 2021-01-07
JP2022088631A (ja) 2022-06-14
JP2021517560A (ja) 2021-07-26
BR112020022833A2 (pt) 2021-02-02
AU2023200562A1 (en) 2023-03-02
EP3743086B1 (en) 2022-03-16
CN112512539A (zh) 2021-03-16
LT3743086T (lt) 2022-06-10
HRP20220578T1 (hr) 2022-09-16
EP3790564A1 (en) 2021-03-17
CY1125211T1 (el) 2024-02-16
ES2916601T3 (es) 2022-07-04
IL278471A (enExample) 2020-12-31
KR20210008391A (ko) 2021-01-21
KR20210008393A (ko) 2021-01-21
DK3743086T3 (da) 2022-05-02
AU2019267171A1 (en) 2021-01-07
CN112601534A (zh) 2021-04-02
SMT202200217T1 (it) 2022-07-21
WO2019215345A1 (en) 2019-11-14
EP4056192A1 (en) 2022-09-14
JP7058449B2 (ja) 2022-04-22
SG11202011028SA (en) 2020-12-30
EP3743086A1 (en) 2020-12-02
IL278471B1 (en) 2023-04-01
SI3743086T1 (sl) 2022-05-31
JP2021523895A (ja) 2021-09-09
EP4066845A1 (en) 2022-10-05
PL3743086T3 (pl) 2022-06-20
WO2019215346A1 (en) 2019-11-14
MX2020012061A (es) 2022-10-13
US20210275605A1 (en) 2021-09-09
MD3743086T2 (ro) 2022-12-31
TW202011975A (zh) 2020-04-01
US20210052671A1 (en) 2021-02-25
TW202014513A (zh) 2020-04-16
SG11202011031UA (en) 2020-12-30
RS63273B1 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
IL278471B2 (en) compounds containing bacterial strains
Prevosto et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction
CN114786687A (zh) 用于过继细胞疗法的Cbl抑制剂和组合物
Ren et al. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell
US11419931B2 (en) Compositions comprising bacterial strains
Zhu et al. Modulation of cytokines production, granzyme B and perforin in murine CIK cells by Ganoderma lucidum polysaccharides
Roper et al. Prostaglandin E2 and cAMP promote B lymphocyte class switching to IgG1
EP3940063A2 (en) Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
Bosschem et al. Species‐specific immunity to Helicobacter suis
US20030119776A1 (en) Modulation of Fas and FasL expression
CN117018036A (zh) 巨球形菌属细菌在制备治疗癌症的药物中的应用
Shirshev et al. Roles of leptin and ghrelin in the regulation of the phenotype and cytokine production by NK cells from peripheral blood
Zheng et al. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models
KR101270999B1 (ko) 결핵균의 Ｒｖ２２９９ｃ 단백질을 이용한 수지상 세포의 성숙방법
CN115887507B (zh) 一种动物乳杆菌在制备抗肿瘤药物中的应用
Gorskaya et al. Effect of immunization with polyvinylpyrrolidone on the counts of stromal precursor cells in the bone marrow and spleen of CBA and CBA/N mice and cytokine gene expression in primary cultures of these cells
JP7828098B2 (ja) Ｔ細胞をｎｋ様細胞にリプログラミングする誘導剤およびその使用
US20050203037A1 (en) Complex immuno-gene medical composition for inhibiting tumor cells
CN114262685A (zh) 常山乙素用于提高nk细胞杀伤力的用途
Choi et al. Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca2+ transport ATPase 2 regulation
KR101264821B1 (ko) 결핵균의 Ｒｖ０５７７ 단백질을 이용한 수지상 세포의 성숙방법
Neris et al. Cytotoxic effects and production of cytokines induced by the endophytic Paenibacillus polymyxa RNC-D in vitro
JP2010142195A (ja) 抗原特異的ヒトＴｈ１７細胞を調整する方法
Chen et al. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells
Zhou et al. Roles of Menin in T cell differentiation and function: Current knowledge and perspectives